---
title: Arrowhead Pharma CEO Sells $85 Million — All Three Filing Insiders Exit to Zero
type: news
slug: arrowhead-pharma-ceo-anzalone-85-million-all-three-insiders-exit-zero-2026
canonical_url: https://13finsight.com/news/arrowhead-pharma-ceo-anzalone-85-million-all-three-insiders-exit-zero-2026
published_at: 2026-02-28T21:24:32.208Z
updated_at: 2026-02-28T21:24:32.924Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 263
locale: en
source: 13F Insight
---

# Arrowhead Pharma CEO Sells $85 Million — All Three Filing Insiders Exit to Zero

> Every insider who recently filed at Arrowhead Pharmaceuticals now holds zero shares. CEO Christopher Anzalone has sold $85.3 million across 170 transactions.

Every insider who recently filed a Form 4 at Arrowhead Pharmaceuticals (ARWR) now holds zero shares. CEO Christopher Richard Anzalone leads the group with $85.3 million in career sales, and all three filing insiders have completely exited their positions. CEO Sells $85.3 Million Over 170 Transactions Anzalone has been one of the most active insider sellers in the biotech sector. Across 170 transactions, the CEO has generated $85.3 million in proceeds. His most recent wave of sales — totaling $24.3 million — brought his share count to exactly zero. For a CEO who has led the company through its pivot to RNA interference therapeutics and a partnership with Amgen, the complete divestiture is notable. Arrowhead's pipeline centers on cardiometabolic and liver diseases, with its lead candidate plozasiran in late-stage trials. Three-for-Three: Complete Exit InsiderTitleCareer SalesTransactionsShares After Christopher AnzaloneChief Executive Officer$85.3M1700 William D. WaddillExecutive$5.9M740 Adeoye Y. OlukotunExecutive$2.5M670 The Supporting Cast William D. Waddill sold $5.9 million across 74 transactions, with $3.4 million in recent sales clearing his position. Adeoye Y. Olukotun sold $2.5 million across 67 transactions, with $1.7 million recently, also exiting completely. Combined, the three insiders generated $93.7 million in career sales across 311 transactions — and collectively hold zero shares of the company. Pipeline Context Arrowhead is a clinical-stage biotech valued at roughly $4 billion. The company's RNAi platform has attracted significant pharma partnerships, but the insider selling comes at a time when several key programs face near-term catalysts. When every actively filing insider has exited, the signal extends beyond routine diversification. Track Arrowhead insider activity on the ARWR stock page.

---

Source: 13F Insight — https://13finsight.com/news/arrowhead-pharma-ceo-anzalone-85-million-all-three-insiders-exit-zero-2026
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-02-28T21:24:32.924Z